Skip to main content
Premium Trial:

Request an Annual Quote

Zeesan Biotech Wins China FDA Approval for HPV Genotyping Assay

NEW YORK (GenomeWeb) – A clinical assay from Zeesan Biotech to detect and identify 14 high-risk genotypes of human papillomavirus has been approved by the China State Food and Drug Administration, company announced recently.

The MeltPro High Risk HPV test, which was CE marked in 2015, is a single-tube, multiplex real-time PCR-based test that uses multicolor melt curve detection. It employs dry reagents, enabling PCR setup to be performed with a single DNA addition step, the Fujian, China-based firm said in a statement. As previously described, the test can be run on any thermal cycler, and it processes as many as 96 cervical swab samples in around 2.5 hours.

Persistent infection of high-risk HPV can cause cervical cancer, and screening is recommended for prevention and early intervention. Many existing assays call out a few common high-risk genotypes, such as HPV 16/18, and typically do not provide information on the identity of other strains present, Zeesan said.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.